Yongmei Yin
As seen in:
Nature,
Wiley,
Wiley Online Library,
MDPI,
JAMA Oncology,
Royal Society of Chemistry,
ONCOLOGY journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Yongmei
Contact Yongmei, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck RackActions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Articles
Yongmei Yin | Authors | CancerNetwork
259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512
SHR-A1811, a novel HER2-targeting antibody-drug conjugate, in advanced solid tumors (HORIZON-X): a global phase 1 trial
|
Abstract SHR-A1811, an antibody‒drug conjugate consisting of the anti-HER2 antibody trastuzumab conjugated via a cleavable linker to a topoisomerase I inhibitor payload, demonstrated substantial antitumor activity in patients with heavily treated HER2-expressing or mutated advanced solid tumors. The main analysis was reported, and this is a long-term follow-up of the HORIZON-X trial (NCT04446260).
By Herui Yao, Min Yan, Zhongsheng Tong, Xinhong Wu, Yongmei Yin, Min-Hee Ryu, John Park, Shusuan Jiang, Jee Hyun Kim, Shouman Wang, Yahua Zhong, Mark Voskoboynik, Jian Zhang, Andreas Kaubisch, Caigang Liu, Yu Chen, Seock-Ah Im, Lingying Wu, Yingbin Liu, Vinod Ganju, Minal Barve, Hui Li, Guangyu Yao, Lequn Bao, Yiming Zhao Verified, Jianli Zhao, Yu Shen, Xiaoyu Zhu, Erwei Song, Mudan Yang, Kaijing Zhao, Shangyi Rong
|
Nature
Verified
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Yongmei
Contact Yongmei, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack